FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
FibroGen (FGEN) Tops Q3 EPS by 21c
November 8, 2016 4:05 PM ESTFibroGen (NASDAQ: FGEN) reported Q3 EPS of ($0.38), $0.21 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $30.1 million versus the consensus estimate of $24.3 million.
For earnings history and earnings-related data on FibroGen (FGEN) click here.
... More